Avycaz Dose Confusion Leads to FDA Medication Error Warning
Government health officials have issued a new warning about the risk of dosing errors with Avycaz, after at least three patients were administered incorrect amounts of the antibacterial drug .
The FDA issued a drug safety communication on September 22, urging healthcare professionals to exercise caution when administering the intravenous drug Avycaz, warning that the label displays the individual strengths of the two active ingredients, not the sum of both. This may increase the risk of potentially dangerous overdoses.
To date, the FDA has received three reports of patients receiving incorrect dosages due to the ambiguity of the strength displayed on the vials labels.
Did You Know?
Millions of Philips CPAP Machines Recalled
Philips DreamStation, CPAP and BiPAP machines sold in recent years may pose a risk of cancer, lung damage and other injuries.Learn More
Avycaz (ceftazidime and avibactam) is an intravenous antibacterial drug used for the treatment of complicated abdominal, urinary tract, and kidney infections. The drug is administered intravenously to patients only by healthcare professionals.
The reports involving Avycaz dose errors were apparently caused by confusion over the strengths displayed on the vial and carton labels. Avycaz contains two active ingredients, 2 grams ceftazidime and .5 grams avibactam. The labels on the vials display the individual strengths of the two ingredients in “2 gram/0.5 gram” format.
In the three incident reports, doctors reportedly misunderstood that the product was based on the sum of the two ingredients, resulting in incorrect dosages administered.
The FDA stated that two errors occurred during the preparation of the dose in the pharmacy and the third case indicated a patient received a higher than intended dose. To date, no injuries or adverse events have been reported.
Despite the risk, the federal regulators are not calling for an Avycaz recall, but rather warning healthcare providers and revising the labels to indicate that the dosage is based on the sum of the two ingredients.
The label revision now indicates that each vial contains 2.5 grams of Avycaz, which is equivalent to 2 grams of ceftazidime and 0.5 grams of avibactam.
"*" indicates required fields
More Top Stories
A new report indicates the U.S. Navy is struggling to process tens of thousands of Camp Lejeune water poisoning claims due to a lack of resources.
A group of plaintiffs have filed a motion with the U.S. JPML seeking consolidation of all Bard implanted port lawsuits before one judge for pretrial proceedings.
A Tepezza hearing loss lawsuit accuses the manufacturer of failing to provide adequate warning about the risks of the thyroid eye disease drug.